tirzepatide compounding pharmacy utah & Semaglutide Weight Loss 1 and GIP therapy Dosing?? - Very Concerned :

Continued government efforts to improve diabetes care are also supporting market growth

The FDA prescribing information for GLP-1 receptor agonists, including semaglutide, notes an increased risk of acute gallbladder disease (cholelithiasis, cholecystitis), which can present with jaundice and elevated liver enzymes that might be mistaken for direct liver injury

These drugs carry FDA boxed warnings due to thyroid C-cell tumours observed in rodent studies, raising concerns for human risk

You need a BMI of 30 or higher (or 27+ with weight-related conditions) to qualify for GLP-1s

Disclaimer The content provided is for informational purposes only and should not be used as a basis for diagnosing or treating any health condition, or for determining actual costs incurred

Giving too little may not yield the intended benefits, while giving too much could potentially cause adverse effects